Asitri Dashboard Search Clinical Trials
The U.S. National Library of Medicine provides a database of clinical trials worldwide. Use the fields below to search the database. Expand your results and select terms or phrases and right-click to search using Google, MalaCards, MedlinePlus, PubMed, or Wikipedia.
Saved Searches
Choose Search
Basic Search
Clinical Trials Search Results
Search History:
Count: 67
Selected: 0
| NCT ID | Title | ||
|---|---|---|---|
| NCT01610479 | A Study of TAS-114 in Combination With S-1 in Patients With Advanced Solid Tumors | ||
| NCT01465464 | Orantinib In Combination With Transcatheter Arterial Chemoembolization In Patients With Unresectable Hepatocellular Carcinoma | ||
| NCT04074343 | TAS-102 and Irinotecan in 2L+ Gastric and Gastroesophageal Adenocarcinoma | ||
| NCT04587908 | A Phase 3 Study of TAS-205 in Patients With Duchenne Muscular Dystrophy（REACH-DMD） | ||
| NCT00142350 | A Study of 5-FUci Versus CPT-11 Plus CDDP Versus S-1 Alone in Advanced Gastric Cancer | ||
| NCT00152243 | A Randomized Controlled Study of Postoperative Adjuvant Chemotherapy of Uracil- Tegafur (UFT) Compared With Surgery Alone (NSAS-GC) | ||
| NCT02128243 | Trial of S-1 Maintenance Therapy in Metastatic Esophagogastric Cancer | ||
| NCT00569790 | Phase II Trial of Combination Therapy With Irinotecan, S-1, and Bevacizumab (IRIS/Bev) in Patients With Unresectable or Recurrent Colorectal Cancer | ||
| NCT00166543 | Three Doses of TAS-108 to Treat Recurrent or Recurrent Inoperable Breast Cancer | ||
| NCT00784290 | Phase I/II Study of TSU-68 for Advanced Hepatocellular Carcinoma | ||
| NCT01534546 | Phase III Study to Compare Perioperative Chemotherapy of Oxaliplatin Combined With S-1(SOX) Versus SOX or Oxaliplatin With Capecitabine (XELOX) as Post-operative Chemotherapy in Locally Advanced Gastric Adenocarcinoma With D2 Dissection | ||
| NCT00202969 | Study of S-1, S-1/CDDP, and 5-FU/CDDP for Advanced Gastric Cancer | ||
| NCT00770874 | Phase III Study of S-1 + Cisplatin vs Cisplatin in Cervical Cancer | ||
| NCT00639327 | Second Line Chemotherapy for S-1 Refractory Advanced Gastric Cancer | ||
| NCT01679340 | A PhaseⅡ Study: SOX vs SP in Adjuvant Chemotherapy After D2 Surgery | ||
| NCT02564367 | Feasibility Study of Adjuvant Treatment With S-1 in Patients After R0-Resection of Adenocarcinoma of the Stomach and Esophagogastric Junction | ||
| NCT00661167 | Phase II Study of ABI-007 for Gastric Cancer | ||
| NCT05773092 | A Phase 2 Study of Osimertinib and S-1 in Treatment Resistant EGFR Mutant NSCLC | ||
| NCT04923529 | TAS-102 in Patients With Advanced, Refractory Pancreatic Adenocarcinoma | ||
| NCT05245968 | A Study of Pimitespib in Combination With Imatinib in Patients With GIST (CHAPTER-GIST-101) | ||
| NCT00737360 | Phase II Study of TAS-106 to Treat Head and Neck Cancer | ||
| NCT05691660 | A Study of TAS3731 in Healthy Adults | ||
| NCT00152230 | A Randomized Controlled Study of Postoperative Adjuvant Chemotherapy of Uracil- Tegafur (UFT) Compared With Surgery Alone (NSAS-CC) | ||
| NCT00721916 | Randomized Phase II Study of SOL for Untreated Metastatic Colorectal Cancer | ||
| NCT00229424 | Verification Study on Lafutidine in Mild Reflux Oesophagitis - Double Blind Controlled Study With Famotidine - | ||
| NCT00429858 | Gemcitabine and S-1 for Locally Advanced Unresectable or Metastatic Pancreatic Cancer | ||
| NCT00152217 | Adjuvant Chemotherapy Trial of TS-1 for Gastric Cancer (ACTS-GC) | ||
| NCT02562807 | A Study of TAS-303 in Female Patients With Stress Urinary Incontinence | ||
| NCT02322593 | Phase III Study of TAS-118 Plus Oxaliplatin Versus S-1 Plus Cisplatin in Patients With Advanced Gastric Cancer | ||
| NCT00152178 | The Comparative Trial of UFT + TAM With CMF + TAM in Adjuvant Therapy for Breast Cancer (CUBC) | ||
| NCT04512053 | A Phase 2 Study of TAS-303 in Female Patients With Stress Urinary Incontinence | ||
| NCT01811277 | SOX Sequential S-1 in Advanced Biliary Tract Carcinoma（BTC）and Pancreatic Cancer | ||
| NCT02943733 | Safety of TAS-102 in Combination With Temozolomide for Metastatic Pancreatic NETs | ||
| NCT00077142 | TAC-101 in Treating Patients With Advanced Hepatocellular Carcinoma (Liver Cancer) | ||
| NCT01824459 | S-1+Oxaliplatin vs.S-1+Cisplatin First-line Treatment of Advanced or Recurrent Non-intestinal Type Gastric Adenocarcinoma Patients | ||
| NCT00569699 | Phase II Trial of Combination Therapy With Bevacizumab and S-1 in Elderly Patients With Unresectable or Recurrent Colorectal Cancer (BASIC) | ||
| NCT05335499 | A Phase 2a Study of TAS5315 in Patients With Chronic Spontaneous Urticaria | ||
| NCT02024841 | Intraperitoneal Docetaxel With Cisplatin and TS-ONE for Gastric Cancer With Peritoneal Carcinomatosis | ||
| NCT01955837 | Study of Trifluridine/Tipiracil (TAS-102) in Patients With Metastatic Colorectal Cancer in Asia | ||
| NCT00150670 | Randomized Phase III Study of TS-1 Alone Versus TS-1 Plus CDDP in Advanced Gastric Cancer | ||
| NCT00891332 | Study of S-1 Plus LV for Untreated Metastatic Colorectal Cancer | ||
| NCT04920032 | Study of ctDNA Guided Change in Tx for Refractory Minimal Residual Disease in Colon Adenocarcinomas | ||
| NCT03175029 | Exploratory Study of TAC-302 in Detrusor Underactivity Patients With Overactive Bladder. | ||
| NCT00359567 | Comparative Study of Palonosetron With Granisetron as a Control in Patients Receiving Highly Emetogenic Chemotherapy | ||
| NCT00152191 | A Randomized Controlled Study of Postoperative Adjuvant Therapy of Uracil-tegafur (UFT) Compared With Cyclophosphamide/Methotrexate/5-fluorouracil (CMF) in Breast Cancer (NSAS-BC) | ||
| NCT01227239 | Preoperative S-1/OHP With Radiation Therapy for Low-lying Rectal Carcinoma in Neo-adjuvant Setting | ||
| NCT00569335 | Phase II Trial of Combination Therapy With S-1, Irinotecan, and Bevacizumab (SIRB) in Patients With Unresectable or Recurrent Colorectal Cancer | ||
| NCT02752048 | A Phase IIa Study of TAS-205 for Duchenne Muscular Dystrophy | ||
| NCT00498225 | Phase III of Gemcitabine Vs TS-1 Vs Gemcitabine Plus TS-1 in Pancreatic Cancer | ||
| NCT04104139 | TAS-102 With Concurrent Radiation for the Treatment of Untreated Resectable Stage II-III Rectal Cancer |
